Research programme: recombinant human bone morphogenetic protein-2 biosimilar - Biogenomics
Alternative Names: Dibotermin alfa - Biogenomics; Recombinant BMP-2Latest Information Update: 30 Oct 2021
At a glance
- Originator Biogenomics
- Class Calcium regulators; Proteins
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Bone-disorders in India (Parenteral, Implant)
- 16 Jan 2014 Research programme: recombinant human bone morphogenetic protein-2 biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
- 10 Jan 2014 Early research in Bone disorders in India (Implant)